Journal: Foods

Article Title: Sea Buckthorn Pericarp Flavonoids Improve Diet-Induced Hyperlipidemia via Coordinated Modulation of Hepatic Lipid Metabolism and Gut Microbiota

doi: 10.3390/foods15061049

Figure Lengend Snippet: TFSP modulates the expression of ACC, FAS, CPT-1α, PPARα and ATGL proteins in the livers of HFD mice. n = 6 per group. Data are presented as mean ± SD. Different letters above bars indicate statistically significant differences ( p < 0.05) by one-way ANOVA followed by LSD post hoc test.

Article Snippet: Peroxisome proliferator-activated receptor alpha (PPARα) primary antibody (Cat. No. A00600-2), carnitine palmitoyltransferase-1 alpha (CPT-1α) primary antibody (Cat. No. A00917-3), acetyl-CoA carboxylase (ACC) primary antibody (Cat. No. M01802-2), fatty acid synthase (FAS) primary antibody (Cat. No. BA0484), adipose triglyceride lipase (ATGL) primary antibody (Cat. No. A01800-1), and GAPDH primary antibody (Cat. No. BM1623) were obtained from BOSTER Biological Technology Co., Ltd. (Wuhan, China).

Techniques: Expressing

Journal: International journal of oncology

Article Title: USP22 promotes the G1/S phase transition by upregulating FoxM1 expression via β-catenin nuclear localization and is associated with poor prognosis in stage II pancreatic ductal adenocarcinoma.

doi: 10.3892/ijo.2014.2531

Figure Lengend Snippet: Figure 6. USP22 expression affects FoxM1 expression and Wnt/β-catenin pathway activation. (A) Triple IF staining for FoxM1 (red), β-catenin (green) and nuclei (DAPI, blue) was performed on PANC-1 cells that were transfected by control-siRNA, USP22-siRNA-1 (50 nM) or USP22-siRNA-2 (150 nM). (B) Triple IF staining for FoxM1 (red), β-catenin (green) and nuclei (DAPI, blue) was performed on CFPAC-1 cells that were transfected by vector USP22-1 (2 µg) or USP22-2 (10 µg). (C and D) RT-PCR and western blot analysis of FoxM1 and β-catenin in PANC-1 cells that were transfected by control- siRNA, USP22‑siRNA-1 (50 nM) or USP22-siRNA-2 (150 nM) (left panel) and CFPAC-1 cells that were transfected by vector, USP22-1 (2 µg) or USP22-2 (10 µg) (right panel). (E) Cellular levels of Axin2, c-Myc and LEF-1 in PANC-1 cells that were transfected by control-siRNA, USP22-siRNA-1 (50 nM) or USP22‑siRNA-2 (150 nM) (left panel) and CFPAC-1 cells that were transfected by vector, USP22-1 (2 µg) or USP22-2 (10 µg) (right panel). (F) Activities of TOP-Flash and FOP-Flash in PANC-1 cells that were transfected by control-siRNA, USP22-siRNA-1 (50 nM) or USP22-siRNA-2 (150 nM) (left panel) and CFPAC-1 cells that were transfected by vector, USP22-1 (2 µg) or USP22-2 (10 µg) (right panel). (G) Cytoplasmic and nuclear levels of FoxM1 and β-catenin in PANC-1 cells that were transfected by control-siRNA, USP22-siRNA-1 (50 nM) or USP22-siRNA-2 (150 nM). (H) Cytoplasmic and nuclear levels of FoxM1 and β-catenin in CFPAC-1 cells that were transfected by vector USP22-1 (2 µg) or USP22-2 (10 µg).

Article Snippet: Membranes were blocked in a buffer (TBS: 50 mM Tris-HCl, 150 mM NaCl, pH 7.4) containing 5% bovine serum albumin and 0.1% Tween-20, followed by incubation with the primary antibodys USP22 (ab4812, 1:2,000, Abcam), FoxM1 (SC-502, 1:200, Santa Cruz Biotechnology), cyclin D1 (60186-1-lg, 1:100), p21 (10355-1-AP, 1:100), p27 (10567-1-AP, 1:100), cdk4 (11026-1-AP, 1:500), cdk6 (14052-1-AP, 1:500, all from Proteintech, Chicago, IL, USA), β-catenin (SC-7963, 1:500, Santa Cruz Biotechnology), Axin2 (EPR2005-2, 1:2,000), LEF (EP2030Y, 1:2,000, both from Abcam), c-Myc (10057-1-AP, 1:200) and LMNB1 (12987-1-AP, 1:1,000) or β-actin (20536-1-AP, 1:2,000, all from Proteintech) diluted in the same buffer.

Techniques: Expressing, Activation Assay, Staining, Transfection, Control, Plasmid Preparation, Reverse Transcription Polymerase Chain Reaction, Western Blot

Journal: Clinical and Experimental Medicine

Article Title: CD59 silencing enhances doxorubicin sensitivity in DLBCL cells and is associated with poor prognosis in patients treated with CHOP regimen

doi: 10.1007/s10238-026-02134-2

Figure Lengend Snippet: Validation of CD59 knock-down in DLBCL cell lines. ( A ) Representative immunoblots showing CD59 protein levels in SU-DHL-4 and U2932 cell lines transfected with three distinct CD59-shRNA constructs or control vectors. β-actin served as the loading control. ( B and C ) Quantitative analysis of relative CD59 mRNA (by qRT-PCR) and protein (by densitometry) levels in SU-DHL-4 (B) and U2932 (C) cells. Data are presented as mean ± SD and normalized to the blank control group.** p < 0.01; *** p < 0.001

Article Snippet: Anti-CD59 antibody (BM5003), RIPA lysis buffer (AR0105), and protease inhibitor (AR1178) were sourced from Boster Biological Technology Co., Ltd.

Techniques: Biomarker Discovery, Knockdown, Western Blot, Transfection, shRNA, Construct, Control, Quantitative RT-PCR

Journal: Clinical and Experimental Medicine

Article Title: CD59 silencing enhances doxorubicin sensitivity in DLBCL cells and is associated with poor prognosis in patients treated with CHOP regimen

doi: 10.1007/s10238-026-02134-2

Figure Lengend Snippet: CD59 knock-down promotes G0/G1 cell-cycle arrest in SU-DHL-4 and U2932 cells. ( A and B ) Representative propidium-iodide histograms for wild-type and shCD59 transduced SU-DHL-4 (A) and U2932 (B) cells under indicated treatments. ( C ) Bar graph summarizing the proportions of cells in G0/G1, S, and G2/M phases for SU-DHL-4 (left) and U2932 (right) cell lines. * p < 0.05, ** p < 0.01, *** p < 0.001

Article Snippet: Anti-CD59 antibody (BM5003), RIPA lysis buffer (AR0105), and protease inhibitor (AR1178) were sourced from Boster Biological Technology Co., Ltd.

Techniques: Knockdown

Journal: Clinical and Experimental Medicine

Article Title: CD59 silencing enhances doxorubicin sensitivity in DLBCL cells and is associated with poor prognosis in patients treated with CHOP regimen

doi: 10.1007/s10238-026-02134-2

Figure Lengend Snippet: CD59 knock-down enhances drug-induced apoptosis in DLBCL cell lines. (A-B) Representative Annexin V-PE/7-AAD flow-cytometry plots for wild-type and shCD59 transduced SU-DHL-4 ( A ) and U2932 ( B ) cells under the indicated treatments. ( C ) Bar-graph summarizing the percentage of early + late apoptotic cells. ns p > 0.05, * p < 0.05, ** p < 0.01*** p < 0.001

Article Snippet: Anti-CD59 antibody (BM5003), RIPA lysis buffer (AR0105), and protease inhibitor (AR1178) were sourced from Boster Biological Technology Co., Ltd.

Techniques: Knockdown, Flow Cytometry

Journal: Clinical and Experimental Medicine

Article Title: CD59 silencing enhances doxorubicin sensitivity in DLBCL cells and is associated with poor prognosis in patients treated with CHOP regimen

doi: 10.1007/s10238-026-02134-2

Figure Lengend Snippet: Representative immunohistochemical staining of CD59 in DLBCL tissue specimens. Images show CD59 expression at both 200× (upper panels) and 400× (lower panels) magnification. Representative fields were classified as negative, weakly positive, and positive for CD59 expression. Scale bars: 50 μm (200×) and 20 μm (400×)

Article Snippet: Anti-CD59 antibody (BM5003), RIPA lysis buffer (AR0105), and protease inhibitor (AR1178) were sourced from Boster Biological Technology Co., Ltd.

Techniques: Immunohistochemical staining, Staining, Expressing

Journal: Clinical and Experimental Medicine

Article Title: CD59 silencing enhances doxorubicin sensitivity in DLBCL cells and is associated with poor prognosis in patients treated with CHOP regimen

doi: 10.1007/s10238-026-02134-2

Figure Lengend Snippet: Progression-free (PFS) and overall survival (OS) analyses based on CD59 expression status in DLBCL. (A and B) Kaplan-Meier curves representing PFS ( A ) and OS ( B ) for 36 CHOP-treated patients stratified by CD59 immunostaining. (C and D) Kaplan-Meier curves representing PFS ( C ) and OS ( D ) for 67 patients who received R-CHOP. (E and F) Kaplan-Meier curves representing PFS ( E ) and OS ( F ) for entire cohort according to CD59 expression. P-values were calculated with the log-rank test

Article Snippet: Anti-CD59 antibody (BM5003), RIPA lysis buffer (AR0105), and protease inhibitor (AR1178) were sourced from Boster Biological Technology Co., Ltd.

Techniques: Expressing, Immunostaining

Journal: Journal of xenobiotics

Article Title: Assessment of the In Vitro Phosphatidylinositol Glycan Class A (PIG-A) Gene Mutation Assay Using Human TK6 and Mouse Hepa1c1c7 Cell Lines.

doi: 10.3390/jox14030073

Figure Lengend Snippet: Figure 1. Mutant cell enrichment by separation with anti-CD59 microbeads and paramagnetic separator.

Article Snippet: Anti-mouse PE-conjugated CD59 antibody (Clone REA287, Lot no. 5230105732), anti-human PE-conjugated CD59 antibody (Clone REA496, Lot no. 1322120604), lyophilized anti-PE MicroBeads (Lot no. 5181221156), LS columns (Lot no. 5180927085), and a QuadroMACS separator were purchased from Miltenyi Biotec (Bergisch Gladbach, Germany).

Techniques: Mutagenesis

Journal: Journal of xenobiotics

Article Title: Assessment of the In Vitro Phosphatidylinositol Glycan Class A (PIG-A) Gene Mutation Assay Using Human TK6 and Mouse Hepa1c1c7 Cell Lines.

doi: 10.3390/jox14030073

Figure Lengend Snippet: Figure 8. PIG-A gating strategy: (a) gating strategies for separating GPI(−) (lower left region) and GPI(+) (lower right region) of TK6 cell line; (b) gating strategies for separating GPI(−) (lower left region) and GPI(+) (lower right region) of Hepa1c1c7 cell line. PIG-A gene mutated cells were not stained with anti-CD59 antibodies and had no PE signal that was conjugated with antibodies.

Article Snippet: Anti-mouse PE-conjugated CD59 antibody (Clone REA287, Lot no. 5230105732), anti-human PE-conjugated CD59 antibody (Clone REA496, Lot no. 1322120604), lyophilized anti-PE MicroBeads (Lot no. 5181221156), LS columns (Lot no. 5180927085), and a QuadroMACS separator were purchased from Miltenyi Biotec (Bergisch Gladbach, Germany).

Techniques: Staining